Please login to the form below

Not currently logged in

Havas’ UK Nurofen campaign to cost £3m

Reckitt Benckiser rolls out TV advertisements in time for flu and cold season
Nurofen campaign

Havas has created a new TV campaign to promote Reckitt Benckiser's painkiller Nurofen in time for flu and cold season.

The campaign for Nurofen was launched on October 28 and will appear on prime time and key daytime TV across a range of terrestrial and other stations.

Part of a £3m promotional campaign, the ad will support the full New Nurofen Cold and Flu Adult range with an emphasis on the Nurofen Cold & Flu Relief GSL line.

The ad, which continues with the brand's 'Lives bigger than pain' theme, is expected to reach more than 85 per cent of the UK's adult population. It will underline how the Nurofen Cold & Flu range can help people carry on through the winter months without winter ailments taking charge.

The TV campaign will be supported by other activity including underground promotion and social media activity. Havas, the agency behind the ad, was also responsible for last winter's Nurofen TV campaign, which marked the brand's launch into the cold and flu category.

Available in more than 40 countries, Nurofen is the fastest growing analgesic brand globally and the leading analgesic brand in UK, Australia and New Zealand, according to owner Reckitt Benckiser.

Article by
Tara Craig

31st October 2013

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...